Can Influenza A Cause Elevated Liver Function Tests?
Yes, influenza A infection commonly causes elevated liver function tests, particularly in severe disease, and these elevations are associated with worse clinical outcomes and higher mortality.
Pattern and Frequency of LFT Abnormalities
Influenza A causes deranged liver function tests in a substantial proportion of infected patients, with the pattern varying by disease severity:
- In avian influenza A (H5N1), deranged LFTs occurred in 29-100% of pediatric cases and 80-100% of adult cases, with elevated ALT specifically documented in 14-100% of children and 60-100% of adults 1
- In seasonal influenza, approximately 11-12% of pediatric patients with acute respiratory infections show elevated liver enzymes, with influenza B showing the highest rate at 24.4%, followed by other respiratory viruses 2
- Comparative data shows abnormal liver tests (ALT or AST ≥40 IU/mL) are common in hospitalized influenza patients, with most elevations being mild to moderate 3
Clinical Significance and Prognostic Implications
The presence of elevated LFTs in influenza A infection carries important prognostic weight:
- Mortality association: Deranged LFTs were associated with poorer prognosis in avian influenza H5N1, particularly when combined with lymphopenia 1
- Severe elevations matter most: Death occurred mainly in patients with severe liver test abnormalities (>200 IU/L), affecting 38.7% of influenza patients with this degree of elevation 3
- Independent predictor: In multivariate analysis controlling for age, sex, lymphopenia, and C-reactive protein, liver test abnormalities remained significantly associated with death (odds ratio 4.344; 95% CI 2.218-8.508) 3
Mechanisms of Liver Injury
Influenza A causes hepatic dysfunction through multiple pathways, not direct viral hepatotropism:
- Systemic inflammation: The liver injury reflects disease severity and systemic inflammatory response rather than direct viral invasion of hepatocytes 3
- Hypoxic hepatitis: In severe cases with septic shock and pneumonia, centrilobular hepatocyte necrosis can occur due to reduced hepatic oxygen supply, particularly in patients with pre-existing conditions like anemia or chronic renal failure 4
- Hepatic decompensation: Patients with pre-existing cirrhosis can develop acute decompensation during influenza A infection, manifesting as ascites, hepatic encephalopathy, and peripheral edema, though this typically resolves within one month 5
Temporal Pattern
The timing of LFT elevation differs from other viral respiratory infections:
- Earlier peak in influenza: The majority of influenza patients show transaminase peaks earlier during hospitalization compared to SARS-CoV-2 patients, though both infections show similar overall patterns 3
- Onset timing: In severe cases, hepatic manifestations typically develop 2-4 days after respiratory symptoms begin 1
Clinical Management Considerations
When encountering elevated LFTs in influenza A patients:
- Rule out alternative causes: Always check hepatitis B surface antigen and anti-hepatitis C virus antibody when LFTs are abnormal, as you would under normal circumstances 1
- Monitor severity markers: Elevated LFTs correlate with other markers of severe disease including lymphopenia, thrombocytopenia, and hypoalbuminemia 1
- Generally transient: Hepatic dysfunction is typically transient and does not require special treatment beyond supportive care 1
- Consider complications: When liver function continues to deteriorate, consider complications such as myositis (especially when AST exceeds ALT), ischemia, cytokine release syndrome, and drug-induced liver injury 1
Critical Pitfalls to Avoid
- Don't assume mild respiratory symptoms exclude severe hepatic involvement: Cases exist where hemodialysis patients with mild respiratory symptoms developed severe hepatitis and liver failure from influenza A 6
- Don't delay antiviral treatment: Patients with severe illness may benefit from antiviral therapy even beyond 48 hours of symptom onset 1
- Don't overlook pre-existing liver disease: Patients with cirrhosis or awaiting transplantation are at particular risk for hepatic decompensation and require close monitoring and vaccination 5